PT-141 peptide reference material for in-vitro laboratory research and analytical method development. Research use only. Not for human or veterinary use; no therapeutic, preventive, or diagnostic claims are made or implied.
Lot testing is in progress. A published COA is not yet available for this lot.
Shipping and taxes at checkout. Inventory is checked when adding to your bag.
Vectra publishes the laboratory certificate for every lot it releases. No released lot certificate is available for this size yet, so no current-lot results are shown.
Browse the COA libraryNo released COA is available for this lot.
Check document status| Analysis | Result | Status |
|---|---|---|
| Analytical results | Not available | No report |
Analytical results are not supplied until a certificate is released.
Check the printed lot on your vial against the certificate card that matches it.
PT-141 peptide reference material for in-vitro laboratory research and analytical method development. Research use only. Not for human or veterinary use; no therapeutic, preventive, or diagnostic claims are made or implied.
Explore published literature Search PubMed for PT-141Refer to the product label and lot-specific documentation for storage and handling instructions.
PT-141 supplied in the selected 15 mg Nasal Spray · 15 mL presentation. Other supplies are listed separately unless explicitly included in an offer.
Open the certificate attached to this product and check that the lot matches your unit. If a report is missing, contact Vectra with the product code and lot.
PT-141 is a synthetic alpha-melanocyte-stimulating hormone analogue, heptapeptide of 7 amino acids. Based on alpha-melanocyte-stimulating hormone (alpha-MSH).
Reported to activate central nervous system melanocortin receptors MC3R and MC4R. Its reported site of action is central, not vascular — which is what distinguishes it from PDE5 inhibitors. We make no claim as to mechanism or effect.
An FDA-approved product containing this moiety exists, approved 2019 for one indication in one population under its own labelling. A research-use reference material is not that product.
Originally developed by Palatin Technologies, evaluated in Phase 3 trials for hypoactive sexual desire disorder in premenopausal women, and approved by FDA in 2019. First described by Palatin Technologies.
Studied in melanocortin receptor signalling. We supply it as a reference material for in-vitro laboratory research and analytical method development only.
Approved for one indication in one population on Phase 3 evidence. Off-label use in men is reported but is not what the approval covers.
Explore the published literature on PT-141. Start with the original papers, study methods and reported limitations.
Publications describe research on the molecule. They do not verify the identity, purity or performance of a Vectra product lot. See the lot-specific COA for product testing.
Your vial’s QR brings you to the product page, with its published COA alongside the product details.
These products are intended for laboratory research. Not for human or veterinary use.
PT-141 peptide reference material for in-vitro laboratory research and analytical method development. Research use only. Not for human or veterinary use; no therapeutic, preventive, or diagnostic claims are made or implied.
Lot testing is in progress. A published COA is not yet available for this lot.
Shipping and taxes at checkout. Inventory is checked when adding to your bag.
Vectra publishes the laboratory certificate for every lot it releases. No released lot certificate is available for this size yet, so no current-lot results are shown.
Browse the COA libraryNo released COA is available for this lot.
Check document status| Analysis | Result | Status |
|---|---|---|
| Analytical results | Not available | No report |
Analytical results are not supplied until a certificate is released.
Check the printed lot on your vial against the certificate card that matches it.
PT-141 peptide reference material for in-vitro laboratory research and analytical method development. Research use only. Not for human or veterinary use; no therapeutic, preventive, or diagnostic claims are made or implied.
Explore published literature Search PubMed for PT-141Refer to the product label and lot-specific documentation for storage and handling instructions.
PT-141 supplied in the selected 15 mg Nasal Spray · 15 mL presentation. Other supplies are listed separately unless explicitly included in an offer.
Open the certificate attached to this product and check that the lot matches your unit. If a report is missing, contact Vectra with the product code and lot.
PT-141 is a synthetic alpha-melanocyte-stimulating hormone analogue, heptapeptide of 7 amino acids. Based on alpha-melanocyte-stimulating hormone (alpha-MSH).
Reported to activate central nervous system melanocortin receptors MC3R and MC4R. Its reported site of action is central, not vascular — which is what distinguishes it from PDE5 inhibitors. We make no claim as to mechanism or effect.
An FDA-approved product containing this moiety exists, approved 2019 for one indication in one population under its own labelling. A research-use reference material is not that product.
Originally developed by Palatin Technologies, evaluated in Phase 3 trials for hypoactive sexual desire disorder in premenopausal women, and approved by FDA in 2019. First described by Palatin Technologies.
Studied in melanocortin receptor signalling. We supply it as a reference material for in-vitro laboratory research and analytical method development only.
Approved for one indication in one population on Phase 3 evidence. Off-label use in men is reported but is not what the approval covers.
Explore the published literature on PT-141. Start with the original papers, study methods and reported limitations.
Publications describe research on the molecule. They do not verify the identity, purity or performance of a Vectra product lot. See the lot-specific COA for product testing.
Your vial’s QR brings you to the product page, with its published COA alongside the product details.
These products are intended for laboratory research. Not for human or veterinary use.
Our sources carry no CAS number, formula, molecular weight, sequence, safety data, or storage data for PT-141.
An approved product containing this moiety exists (2019). This material is supplied for in-vitro research use only. No therapeutic, preventive, or diagnostic claims are made or implied.
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.
Our sources carry no CAS number, formula, molecular weight, sequence, safety data, or storage data for PT-141.
An approved product containing this moiety exists (2019). This material is supplied for in-vitro research use only. No therapeutic, preventive, or diagnostic claims are made or implied.
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.
